AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. EVTL
  4. [6-K] Vertical Aerospace Ltd. Current Report (Foreign Issuer)

[6-K] Vertical Aerospace Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Redmile Group, LLC, Jeremy C. Green and RedCo II Master Fund, L.P. have filed Amendment No. 9 to their Schedule 13D on Fate Therapeutics, Inc. (NASDAQ: FATE). The filing, triggered by an event dated 07 July 2025, updates the group鈥檚 ownership disclosure and key blocking provisions.

  • Aggregate beneficial ownership: 17,941,579 common shares (direct and deemed) representing 14.9 % of FATE鈥檚 outstanding common stock (114,633,022 shares as of 6 May 2025).
  • Key holder detail: RedCo II Master Fund holds 13,479,013 shares (11.3 %). All shares are subject to shared voting and dispositive power; no reporting person has sole power.
  • Warrants & preferred stock: 鈥� Pre-Funded Warrants covering 3,691,324 shares (exercise price $0.001) 鈥� Class A Preferred Stock convertible 1-for-5 into up to 810,065 shares (RedCo II) and additional preferred shares across other Redmile funds.
    Both instruments are governed by 14.99 % beneficial-ownership blockers.
  • Change in blocker threshold: On 1 July 2025 Redmile elected to raise the 鈥淢aximum Percentage鈥� under the Warrant Beneficial Ownership Blocker from 9.99 % to 14.99 % (effective 61 days later). This allows the group to exercise additional warrants and approach the new 14.99 % cap without breaching Section 13(d) limits.
  • Funding source: Working capital of various Redmile-managed private investment funds (no external financing disclosed).
  • Historical context: This is the ninth amendment to an initial 13D filed in 2018, reflecting the evolution of Redmile鈥檚 position and security mix (common, warrants, preferred, options, RSUs).

The amendment does not announce new purchases or sales but formalises the larger ownership cap, clarifies the composition of the beneficial stake, and reiterates blocker mechanics designed to limit ownership to 14.99 % of outstanding commons.

Redmile Group, LLC, Jeremy C. Green e RedCo II Master Fund, L.P. hanno presentato l'Emendamento n. 9 al loro Schedule 13D riguardante Fate Therapeutics, Inc. (NASDAQ: FATE). La comunicazione, scaturita da un evento datato 7 luglio 2025, aggiorna la dichiarazione di propriet脿 del gruppo e le principali disposizioni di blocco.

  • Propriet脿 aggregata effettiva: 17.941.579 azioni ordinarie (dirette e considerate) che rappresentano il 14,9 % del capitale sociale ordinario di FATE (114.633.022 azioni al 6 maggio 2025).
  • Dettaglio del principale detentore: RedCo II Master Fund detiene 13.479.013 azioni (11,3 %). Tutte le azioni sono soggette a poteri condivisi di voto e disposizione; nessuna persona segnalante ha potere esclusivo.
  • Warrant e azioni privilegiate: 鈥� Warrant pre-finanziati che coprono 3.691.324 azioni (prezzo di esercizio $0,001) 鈥� Azioni privilegiate di Classe A convertibili 1-per-5 fino a un massimo di 810.065 azioni (RedCo II) e azioni privilegiate aggiuntive in altri fondi gestiti da Redmile.
    Entrambi gli strumenti sono soggetti a limiti di propriet脿 effettiva del 14,99 %.
  • Modifica della soglia di blocco: Il 1 luglio 2025 Redmile ha scelto di aumentare la 鈥淧ercentuale Massima鈥� nel Blocco di Propriet脿 Beneficiaria dei Warrant dal 9,99 % al 14,99 % (efficace 61 giorni dopo). Ci貌 consente al gruppo di esercitare ulteriori warrant e avvicinarsi al nuovo limite del 14,99 % senza violare i limiti della Sezione 13(d).
  • Fonte di finanziamento: Capitale operativo di vari fondi di investimento privati gestiti da Redmile (nessun finanziamento esterno dichiarato).
  • Contesto storico: Questo 猫 il nono emendamento a un 13D iniziale presentato nel 2018, che riflette l鈥檈voluzione della posizione e della composizione degli strumenti di Redmile (azioni ordinarie, warrant, privilegiate, opzioni, RSU).

L鈥檈mendamento non annuncia nuovi acquisti o vendite, ma formalizza il limite maggiore di propriet脿, chiarisce la composizione della partecipazione effettiva e ribadisce i meccanismi di blocco volti a limitare la propriet脿 al 14,99 % delle azioni ordinarie in circolazione.

Redmile Group, LLC, Jeremy C. Green y RedCo II Master Fund, L.P. han presentado la Enmienda No. 9 a su Schedule 13D sobre Fate Therapeutics, Inc. (NASDAQ: FATE). La presentaci贸n, motivada por un evento fechado el 7 de julio de 2025, actualiza la divulgaci贸n de propiedad del grupo y las disposiciones clave de bloqueo.

  • Propiedad beneficiosa agregada: 17,941,579 acciones comunes (directas y consideradas) que representan el 14.9 % del capital social com煤n en circulaci贸n de FATE (114,633,022 acciones al 6 de mayo de 2025).
  • Detalle del titular clave: RedCo II Master Fund posee 13,479,013 acciones (11.3 %). Todas las acciones est谩n sujetas a poderes compartidos de voto y disposici贸n; ninguna persona reportante tiene poder exclusivo.
  • Warrants y acciones preferentes: 鈥� Warrants prefinanciados que cubren 3,691,324 acciones (precio de ejercicio $0.001) 鈥� Acciones preferentes Clase A convertibles 1 a 5 hasta un m谩ximo de 810,065 acciones (RedCo II) y acciones preferentes adicionales en otros fondos de Redmile.
    Ambos instrumentos est谩n sujetos a bloqueadores de propiedad beneficiosa del 14.99 %.
  • Cambio en el umbral del bloqueador: El 1 de julio de 2025 Redmile eligi贸 aumentar el 鈥淧orcentaje M谩ximo鈥� bajo el Bloqueador de Propiedad Beneficiosa de Warrants del 9.99 % al 14.99 % (efectivo 61 d铆as despu茅s). Esto permite al grupo ejercer warrants adicionales y acercarse al nuevo l铆mite del 14.99 % sin infringir los l铆mites de la Secci贸n 13(d).
  • Fuente de financiamiento: Capital de trabajo de varios fondos de inversi贸n privados gestionados por Redmile (no se revel贸 financiamiento externo).
  • Contexto hist贸rico: Esta es la novena enmienda a un 13D inicial presentado en 2018, reflejando la evoluci贸n de la posici贸n y la mezcla de valores de Redmile (acciones comunes, warrants, preferentes, opciones, RSU).

La enmienda no anuncia nuevas compras o ventas, pero formaliza el l铆mite mayor de propiedad, aclara la composici贸n de la participaci贸n beneficiosa y reitera los mecanismos de bloqueo dise帽ados para limitar la propiedad al 14.99 % de las acciones comunes en circulaci贸n.

Redmile Group, LLC, Jeremy C. Green 氚� RedCo II Master Fund, L.P.電� Fate Therapeutics, Inc. (NASDAQ: FATE)鞐� 雽�頃� Schedule 13D 靾橃爼鞎� 9順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 2025云� 7鞗� 7鞚�鞛� 鞚措菠韸胳棎 鞚橅暣 齑夒皽霅� 鞚措矆 鞝滌稖鞚� 攴鸽９鞚� 靻岇湢甓� 瓿店皽 氚� 欤检殧 彀嫧 臁绊暛鞚� 鞐呺嵃鞚错姼頃╇媹雼�.

  • 齑� 鞁れ 靻岇湢甓�: 17,941,579欤� 氤错喌欤�(歆侅爲 氚� 臧勳＜)搿�, 2025云� 5鞗� 6鞚� 旮办 FATE 氚滍枆 氤错喌欤� 114,633,022欤检潣 14.9 %鞐� 頃措嫻頃╇媹雼�.
  • 欤检殧 氤挫湢鞛� 靹鸽秬靷暛: RedCo II Master Fund電� 13,479,013欤�(11.3 %)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 欤检嫕鞚� 瓿惦彊 韴憸 氚� 觳橂秳 甓岉暅鞚� 雽�靸侅澊氅�, 鞏措枻 氤搓碃鞛愲弰 雼弲 甓岉暅鞚� 臧栮碃 鞛堨 鞎婌姷雼堧嫟.
  • 鞗岆煱韸� 氚� 鞖办劆欤�: 鈥� 頄夓偓 臧�瓴� $0.001鞚� 3,691,324欤茧ゼ 旎る矂頃橂姅 靹犾旮� 鞗岆煱韸� 鈥� 斓滊寑 810,065欤缄箤歆� 1雽� 5 鞝勴櫂 臧�電ロ暅 A 韥措灅鞀� 鞖办劆欤�(RedCo II 氤挫湢) 氚� 旮绊儉 Redmile 韼�霌滌潣 於旉皜 鞖办劆欤�
    霊� 旮堨湹靸來拡 氇憪 14.99 % 鞁れ 靻岇湢甓� 彀嫧 攴滌爼鞐� 霐半雼堧嫟.
  • 彀嫧 鞛勱硠臧� 氤�瓴�: 2025云� 7鞗� 1鞚� Redmile鞚� 鞗岆煱韸� 鞁れ 靻岇湢甓� 彀嫧旮办鞚� 鈥滌禍雽� 牍勳湪鈥濎潉 9.99 %鞐愳劀 14.99 %搿� 靸來枼 臁办爼頃橁赴搿� 瓴办爼頄堨溂氅�(61鞚� 頉� 氚滍毃), 鞚措ゼ 韱淀暣 攴鸽９鞚� 於旉皜 鞗岆煱韸鸽ゼ 頄夓偓頃橁碃 靸堧鞖� 14.99 % 頃滊弰鞐� 攴检爲頃� 靾� 鞛堨溂雮� 13(d) 臁绊暛 頃滊弰毳� 鞙勲皹頃橃 鞎婌姷雼堧嫟.
  • 鞛愱笀 於滌矘: Redmile鞚� 甏�毽晿電� 雼れ枒頃� 靷 韴瀽 韼�霌滌潣 鞖挫爠鞛愲掣(鞕鸽秬 鞛愱笀 臁半嫭鞚� 瓿店皽霅橃 鞎婌潓).
  • 鞐偓鞝� 氚瓣步: 2018雲勳棎 鞝滌稖霅� 齑堦赴 13D鞚� 鞎勴檳 氩堨Ц 靾橃爼鞎堨溂搿�, Redmile鞚� 韽靺橁臣 歃濌秾 甑劚(氤错喌欤�, 鞗岆煱韸�, 鞖办劆欤�, 鞓奠厴, RSU)鞚� 氤�頇旊ゼ 氚橃榿頃╇媹雼�.

鞚措矆 靾橃爼鞎堨潃 鞁犼窚 毵れ垬雮� 毵る弰毳� 氚滍憸頃橃 鞎婌溂氅�, 雿� 韥� 靻岇湢 頃滊弰毳� 瓿奠嫕頇旐晿瓿�, 鞁れ 歆�攵� 甑劚鞚� 氇呿檿頌� 頃橂┌, 氚滍枆 欤检嫕鞚� 14.99 %搿� 靻岇湢甓岇潉 鞝滍暅頃橂姅 彀嫧 氅旍护雼堨鞚� 鞛檿鞚疙暕雼堧嫟.

Redmile Group, LLC, Jeremy C. Green et RedCo II Master Fund, L.P. ont d茅pos茅 l'Amendement n掳 9 脿 leur Schedule 13D concernant Fate Therapeutics, Inc. (NASDAQ : FATE). Ce d茅p么t, d茅clench茅 par un 茅v茅nement dat茅 du 7 juillet 2025, met 脿 jour la divulgation de la propri茅t茅 du groupe et les principales dispositions de blocage.

  • Participation b茅n茅ficiaire agr茅g茅e : 17 941 579 actions ordinaires (directes et r茅put茅es) repr茅sentant 14,9 % du capital social ordinaire en circulation de FATE (114 633 022 actions au 6 mai 2025).
  • D茅tail du d茅tenteur cl茅 : RedCo II Master Fund d茅tient 13 479 013 actions (11,3 %). Toutes les actions sont soumises 脿 un pouvoir conjoint de vote et de disposition ; aucune personne d茅clarant ne dispose d鈥檜n pouvoir exclusif.
  • Bons de souscription et actions privil茅gi茅es : 鈥� Bons pr茅financ茅s couvrant 3 691 324 actions (prix d鈥檈xercice 0,001 $) 鈥� Actions privil茅gi茅es de classe A convertibles au ratio de 1 pour 5 jusqu鈥櫭� 810 065 actions (RedCo II) et actions privil茅gi茅es suppl茅mentaires dans d鈥檃utres fonds Redmile.
    Les deux instruments sont soumis 脿 des seuils de blocage de propri茅t茅 b茅n茅ficiaire de 14,99 %.
  • Modification du seuil de blocage : Le 1er juillet 2025, Redmile a choisi d鈥檃ugmenter le 芦 Pourcentage Maximum 禄 sous le Bloqueur de propri茅t茅 b茅n茅ficiaire des bons de souscription de 9,99 % 脿 14,99 % (effet 61 jours plus tard). Cela permet au groupe d鈥檈xercer des bons suppl茅mentaires et de s鈥檃pprocher du nouveau plafond de 14,99 % sans enfreindre les limites de la Section 13(d).
  • Source de financement : Fonds de roulement de divers fonds d鈥檌nvestissement priv茅s g茅r茅s par Redmile (aucun financement externe d茅clar茅).
  • Contexte historique : Il s鈥檃git du 苍别耻惫颈猫尘别 amendement 脿 un 13D initial d茅pos茅 en 2018, refl茅tant l鈥櫭﹙olution de la position et de la composition des titres de Redmile (ordinaires, bons, privil茅gi茅es, options, RSU).

L鈥檃mendement n鈥檃nnonce pas de nouveaux achats ou ventes mais formalise le plafond de propri茅t茅 plus 茅lev茅, clarifie la composition de la participation b茅n茅ficiaire et r茅it猫re les m茅canismes de blocage con莽us pour limiter la propri茅t茅 脿 14,99 % des actions ordinaires en circulation.

Redmile Group, LLC, Jeremy C. Green und RedCo II Master Fund, L.P. haben 脛nderung Nr. 9 zu ihrem Schedule 13D bez眉glich Fate Therapeutics, Inc. (NASDAQ: FATE) eingereicht. Die Einreichung, ausgel枚st durch ein Ereignis vom 7. Juli 2025, aktualisiert die Offenlegung des Eigentums der Gruppe und wichtige Sperrbestimmungen.

  • 骋别蝉补尘迟苍耻迟锄苍颈别脽别谤补苍迟别颈濒: 17.941.579 Stammaktien (direkt und als gehalten angesehen), was 14,9 % des ausstehenden Stammkapitals von FATE entspricht (114.633.022 Aktien zum 6. Mai 2025).
  • Details zum Hauptinhaber: RedCo II Master Fund h盲lt 13.479.013 Aktien (11,3 %). Alle Aktien unterliegen gemeinsamer Stimm- und Verf眉gungsgewalt; keine meldende Person hat Alleinmacht.
  • Warrants & Vorzugsaktien: 鈥� Vorfinanzierte Warrants f眉r 3.691.324 Aktien (Aus眉bungspreis $0,001) 鈥� Klasse A Vorzugsaktien, wandelbar 1:5 bis zu 810.065 Aktien (RedCo II) sowie zus盲tzliche Vorzugsaktien in anderen Redmile-Fonds.
    Beide Instrumente unterliegen Sperrgrenzen von 14,99 % des Nutznie脽eranteils.
  • 脛nderung der Sperrschwelle: Am 1. Juli 2025 entschied sich Redmile, den 鈥濵aximalprozentsatz鈥� unter dem Warrant-Nutznie脽er-Sperrmechanismus von 9,99 % auf 14,99 % anzuheben (wirksam 61 Tage sp盲ter). Dies erm枚glicht der Gruppe, zus盲tzliche Warrants auszu眉ben und sich der neuen 14,99 % Grenze zu n盲hern, ohne die Grenzen von Abschnitt 13(d) zu 眉berschreiten.
  • Finanzierungsquelle: Betriebskapital verschiedener von Redmile verwalteter privater Investmentfonds (keine externe Finanzierung angegeben).
  • Historischer Kontext: Dies ist die neunte 脛nderung zu einem urspr眉nglich 2018 eingereichten 13D, die die Entwicklung der Position und der Wertpapierzusammensetzung von Redmile widerspiegelt (Stammaktien, Warrants, Vorzugsaktien, Optionen, RSUs).

Die 脛nderung k眉ndigt keine neuen K盲ufe oder Verk盲ufe an, sondern formalisert die h枚here Eigentumsgrenze, kl盲rt die Zusammensetzung des Nutznie脽eranteils und bekr盲ftigt die Sperrmechanismen, die darauf ausgelegt sind, das Eigentum auf 14,99 % der ausstehenden Stammaktien zu begrenzen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR 鈥� Redmile lifts ownership cap to 14.99 %, reaffirming a large strategic stake without immediate cash impact.

The filing signals continued commitment from a specialist biotech investor. Moving the blocker from 9.99 % to 14.99 % allows Redmile to convert/exercise up to roughly 4.9 million additional shares (options, warrants, preferred) over time. Because the warrants are pre-funded at $0.001, Fate receives negligible incremental cash; the principal impact is potential dilution and voting concentration. No new purchases are disclosed, so near-term float dynamics remain unchanged. Overall, this is structurally important but not fundamentally value-changing in the short term.

TL;DR 鈥� Ownership concentration rises; possible governance influence, but still below 15 % control threshold.

Redmile now controls nearly 15 % of FATE鈥檚 voting power, positioning it as the company鈥檚 leading shareholder. While the firm disclaims control intent, a stake of this size affords meaningful influence over board matters and strategic direction, especially in biotech where floats are limited. The blocker election is a permissible mechanism under SEC rules, but shareholders should watch for future activism or alignment proposals. Because the cap remains below 15 %, poison-pill or change-of-control triggers are unlikely to activate.

Redmile Group, LLC, Jeremy C. Green e RedCo II Master Fund, L.P. hanno presentato l'Emendamento n. 9 al loro Schedule 13D riguardante Fate Therapeutics, Inc. (NASDAQ: FATE). La comunicazione, scaturita da un evento datato 7 luglio 2025, aggiorna la dichiarazione di propriet脿 del gruppo e le principali disposizioni di blocco.

  • Propriet脿 aggregata effettiva: 17.941.579 azioni ordinarie (dirette e considerate) che rappresentano il 14,9 % del capitale sociale ordinario di FATE (114.633.022 azioni al 6 maggio 2025).
  • Dettaglio del principale detentore: RedCo II Master Fund detiene 13.479.013 azioni (11,3 %). Tutte le azioni sono soggette a poteri condivisi di voto e disposizione; nessuna persona segnalante ha potere esclusivo.
  • Warrant e azioni privilegiate: 鈥� Warrant pre-finanziati che coprono 3.691.324 azioni (prezzo di esercizio $0,001) 鈥� Azioni privilegiate di Classe A convertibili 1-per-5 fino a un massimo di 810.065 azioni (RedCo II) e azioni privilegiate aggiuntive in altri fondi gestiti da Redmile.
    Entrambi gli strumenti sono soggetti a limiti di propriet脿 effettiva del 14,99 %.
  • Modifica della soglia di blocco: Il 1 luglio 2025 Redmile ha scelto di aumentare la 鈥淧ercentuale Massima鈥� nel Blocco di Propriet脿 Beneficiaria dei Warrant dal 9,99 % al 14,99 % (efficace 61 giorni dopo). Ci貌 consente al gruppo di esercitare ulteriori warrant e avvicinarsi al nuovo limite del 14,99 % senza violare i limiti della Sezione 13(d).
  • Fonte di finanziamento: Capitale operativo di vari fondi di investimento privati gestiti da Redmile (nessun finanziamento esterno dichiarato).
  • Contesto storico: Questo 猫 il nono emendamento a un 13D iniziale presentato nel 2018, che riflette l鈥檈voluzione della posizione e della composizione degli strumenti di Redmile (azioni ordinarie, warrant, privilegiate, opzioni, RSU).

L鈥檈mendamento non annuncia nuovi acquisti o vendite, ma formalizza il limite maggiore di propriet脿, chiarisce la composizione della partecipazione effettiva e ribadisce i meccanismi di blocco volti a limitare la propriet脿 al 14,99 % delle azioni ordinarie in circolazione.

Redmile Group, LLC, Jeremy C. Green y RedCo II Master Fund, L.P. han presentado la Enmienda No. 9 a su Schedule 13D sobre Fate Therapeutics, Inc. (NASDAQ: FATE). La presentaci贸n, motivada por un evento fechado el 7 de julio de 2025, actualiza la divulgaci贸n de propiedad del grupo y las disposiciones clave de bloqueo.

  • Propiedad beneficiosa agregada: 17,941,579 acciones comunes (directas y consideradas) que representan el 14.9 % del capital social com煤n en circulaci贸n de FATE (114,633,022 acciones al 6 de mayo de 2025).
  • Detalle del titular clave: RedCo II Master Fund posee 13,479,013 acciones (11.3 %). Todas las acciones est谩n sujetas a poderes compartidos de voto y disposici贸n; ninguna persona reportante tiene poder exclusivo.
  • Warrants y acciones preferentes: 鈥� Warrants prefinanciados que cubren 3,691,324 acciones (precio de ejercicio $0.001) 鈥� Acciones preferentes Clase A convertibles 1 a 5 hasta un m谩ximo de 810,065 acciones (RedCo II) y acciones preferentes adicionales en otros fondos de Redmile.
    Ambos instrumentos est谩n sujetos a bloqueadores de propiedad beneficiosa del 14.99 %.
  • Cambio en el umbral del bloqueador: El 1 de julio de 2025 Redmile eligi贸 aumentar el 鈥淧orcentaje M谩ximo鈥� bajo el Bloqueador de Propiedad Beneficiosa de Warrants del 9.99 % al 14.99 % (efectivo 61 d铆as despu茅s). Esto permite al grupo ejercer warrants adicionales y acercarse al nuevo l铆mite del 14.99 % sin infringir los l铆mites de la Secci贸n 13(d).
  • Fuente de financiamiento: Capital de trabajo de varios fondos de inversi贸n privados gestionados por Redmile (no se revel贸 financiamiento externo).
  • Contexto hist贸rico: Esta es la novena enmienda a un 13D inicial presentado en 2018, reflejando la evoluci贸n de la posici贸n y la mezcla de valores de Redmile (acciones comunes, warrants, preferentes, opciones, RSU).

La enmienda no anuncia nuevas compras o ventas, pero formaliza el l铆mite mayor de propiedad, aclara la composici贸n de la participaci贸n beneficiosa y reitera los mecanismos de bloqueo dise帽ados para limitar la propiedad al 14.99 % de las acciones comunes en circulaci贸n.

Redmile Group, LLC, Jeremy C. Green 氚� RedCo II Master Fund, L.P.電� Fate Therapeutics, Inc. (NASDAQ: FATE)鞐� 雽�頃� Schedule 13D 靾橃爼鞎� 9順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 2025云� 7鞗� 7鞚�鞛� 鞚措菠韸胳棎 鞚橅暣 齑夒皽霅� 鞚措矆 鞝滌稖鞚� 攴鸽９鞚� 靻岇湢甓� 瓿店皽 氚� 欤检殧 彀嫧 臁绊暛鞚� 鞐呺嵃鞚错姼頃╇媹雼�.

  • 齑� 鞁れ 靻岇湢甓�: 17,941,579欤� 氤错喌欤�(歆侅爲 氚� 臧勳＜)搿�, 2025云� 5鞗� 6鞚� 旮办 FATE 氚滍枆 氤错喌欤� 114,633,022欤检潣 14.9 %鞐� 頃措嫻頃╇媹雼�.
  • 欤检殧 氤挫湢鞛� 靹鸽秬靷暛: RedCo II Master Fund電� 13,479,013欤�(11.3 %)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 欤检嫕鞚� 瓿惦彊 韴憸 氚� 觳橂秳 甓岉暅鞚� 雽�靸侅澊氅�, 鞏措枻 氤搓碃鞛愲弰 雼弲 甓岉暅鞚� 臧栮碃 鞛堨 鞎婌姷雼堧嫟.
  • 鞗岆煱韸� 氚� 鞖办劆欤�: 鈥� 頄夓偓 臧�瓴� $0.001鞚� 3,691,324欤茧ゼ 旎る矂頃橂姅 靹犾旮� 鞗岆煱韸� 鈥� 斓滊寑 810,065欤缄箤歆� 1雽� 5 鞝勴櫂 臧�電ロ暅 A 韥措灅鞀� 鞖办劆欤�(RedCo II 氤挫湢) 氚� 旮绊儉 Redmile 韼�霌滌潣 於旉皜 鞖办劆欤�
    霊� 旮堨湹靸來拡 氇憪 14.99 % 鞁れ 靻岇湢甓� 彀嫧 攴滌爼鞐� 霐半雼堧嫟.
  • 彀嫧 鞛勱硠臧� 氤�瓴�: 2025云� 7鞗� 1鞚� Redmile鞚� 鞗岆煱韸� 鞁れ 靻岇湢甓� 彀嫧旮办鞚� 鈥滌禍雽� 牍勳湪鈥濎潉 9.99 %鞐愳劀 14.99 %搿� 靸來枼 臁办爼頃橁赴搿� 瓴办爼頄堨溂氅�(61鞚� 頉� 氚滍毃), 鞚措ゼ 韱淀暣 攴鸽９鞚� 於旉皜 鞗岆煱韸鸽ゼ 頄夓偓頃橁碃 靸堧鞖� 14.99 % 頃滊弰鞐� 攴检爲頃� 靾� 鞛堨溂雮� 13(d) 臁绊暛 頃滊弰毳� 鞙勲皹頃橃 鞎婌姷雼堧嫟.
  • 鞛愱笀 於滌矘: Redmile鞚� 甏�毽晿電� 雼れ枒頃� 靷 韴瀽 韼�霌滌潣 鞖挫爠鞛愲掣(鞕鸽秬 鞛愱笀 臁半嫭鞚� 瓿店皽霅橃 鞎婌潓).
  • 鞐偓鞝� 氚瓣步: 2018雲勳棎 鞝滌稖霅� 齑堦赴 13D鞚� 鞎勴檳 氩堨Ц 靾橃爼鞎堨溂搿�, Redmile鞚� 韽靺橁臣 歃濌秾 甑劚(氤错喌欤�, 鞗岆煱韸�, 鞖办劆欤�, 鞓奠厴, RSU)鞚� 氤�頇旊ゼ 氚橃榿頃╇媹雼�.

鞚措矆 靾橃爼鞎堨潃 鞁犼窚 毵れ垬雮� 毵る弰毳� 氚滍憸頃橃 鞎婌溂氅�, 雿� 韥� 靻岇湢 頃滊弰毳� 瓿奠嫕頇旐晿瓿�, 鞁れ 歆�攵� 甑劚鞚� 氇呿檿頌� 頃橂┌, 氚滍枆 欤检嫕鞚� 14.99 %搿� 靻岇湢甓岇潉 鞝滍暅頃橂姅 彀嫧 氅旍护雼堨鞚� 鞛檿鞚疙暕雼堧嫟.

Redmile Group, LLC, Jeremy C. Green et RedCo II Master Fund, L.P. ont d茅pos茅 l'Amendement n掳 9 脿 leur Schedule 13D concernant Fate Therapeutics, Inc. (NASDAQ : FATE). Ce d茅p么t, d茅clench茅 par un 茅v茅nement dat茅 du 7 juillet 2025, met 脿 jour la divulgation de la propri茅t茅 du groupe et les principales dispositions de blocage.

  • Participation b茅n茅ficiaire agr茅g茅e : 17 941 579 actions ordinaires (directes et r茅put茅es) repr茅sentant 14,9 % du capital social ordinaire en circulation de FATE (114 633 022 actions au 6 mai 2025).
  • D茅tail du d茅tenteur cl茅 : RedCo II Master Fund d茅tient 13 479 013 actions (11,3 %). Toutes les actions sont soumises 脿 un pouvoir conjoint de vote et de disposition ; aucune personne d茅clarant ne dispose d鈥檜n pouvoir exclusif.
  • Bons de souscription et actions privil茅gi茅es : 鈥� Bons pr茅financ茅s couvrant 3 691 324 actions (prix d鈥檈xercice 0,001 $) 鈥� Actions privil茅gi茅es de classe A convertibles au ratio de 1 pour 5 jusqu鈥櫭� 810 065 actions (RedCo II) et actions privil茅gi茅es suppl茅mentaires dans d鈥檃utres fonds Redmile.
    Les deux instruments sont soumis 脿 des seuils de blocage de propri茅t茅 b茅n茅ficiaire de 14,99 %.
  • Modification du seuil de blocage : Le 1er juillet 2025, Redmile a choisi d鈥檃ugmenter le 芦 Pourcentage Maximum 禄 sous le Bloqueur de propri茅t茅 b茅n茅ficiaire des bons de souscription de 9,99 % 脿 14,99 % (effet 61 jours plus tard). Cela permet au groupe d鈥檈xercer des bons suppl茅mentaires et de s鈥檃pprocher du nouveau plafond de 14,99 % sans enfreindre les limites de la Section 13(d).
  • Source de financement : Fonds de roulement de divers fonds d鈥檌nvestissement priv茅s g茅r茅s par Redmile (aucun financement externe d茅clar茅).
  • Contexte historique : Il s鈥檃git du 苍别耻惫颈猫尘别 amendement 脿 un 13D initial d茅pos茅 en 2018, refl茅tant l鈥櫭﹙olution de la position et de la composition des titres de Redmile (ordinaires, bons, privil茅gi茅es, options, RSU).

L鈥檃mendement n鈥檃nnonce pas de nouveaux achats ou ventes mais formalise le plafond de propri茅t茅 plus 茅lev茅, clarifie la composition de la participation b茅n茅ficiaire et r茅it猫re les m茅canismes de blocage con莽us pour limiter la propri茅t茅 脿 14,99 % des actions ordinaires en circulation.

Redmile Group, LLC, Jeremy C. Green und RedCo II Master Fund, L.P. haben 脛nderung Nr. 9 zu ihrem Schedule 13D bez眉glich Fate Therapeutics, Inc. (NASDAQ: FATE) eingereicht. Die Einreichung, ausgel枚st durch ein Ereignis vom 7. Juli 2025, aktualisiert die Offenlegung des Eigentums der Gruppe und wichtige Sperrbestimmungen.

  • 骋别蝉补尘迟苍耻迟锄苍颈别脽别谤补苍迟别颈濒: 17.941.579 Stammaktien (direkt und als gehalten angesehen), was 14,9 % des ausstehenden Stammkapitals von FATE entspricht (114.633.022 Aktien zum 6. Mai 2025).
  • Details zum Hauptinhaber: RedCo II Master Fund h盲lt 13.479.013 Aktien (11,3 %). Alle Aktien unterliegen gemeinsamer Stimm- und Verf眉gungsgewalt; keine meldende Person hat Alleinmacht.
  • Warrants & Vorzugsaktien: 鈥� Vorfinanzierte Warrants f眉r 3.691.324 Aktien (Aus眉bungspreis $0,001) 鈥� Klasse A Vorzugsaktien, wandelbar 1:5 bis zu 810.065 Aktien (RedCo II) sowie zus盲tzliche Vorzugsaktien in anderen Redmile-Fonds.
    Beide Instrumente unterliegen Sperrgrenzen von 14,99 % des Nutznie脽eranteils.
  • 脛nderung der Sperrschwelle: Am 1. Juli 2025 entschied sich Redmile, den 鈥濵aximalprozentsatz鈥� unter dem Warrant-Nutznie脽er-Sperrmechanismus von 9,99 % auf 14,99 % anzuheben (wirksam 61 Tage sp盲ter). Dies erm枚glicht der Gruppe, zus盲tzliche Warrants auszu眉ben und sich der neuen 14,99 % Grenze zu n盲hern, ohne die Grenzen von Abschnitt 13(d) zu 眉berschreiten.
  • Finanzierungsquelle: Betriebskapital verschiedener von Redmile verwalteter privater Investmentfonds (keine externe Finanzierung angegeben).
  • Historischer Kontext: Dies ist die neunte 脛nderung zu einem urspr眉nglich 2018 eingereichten 13D, die die Entwicklung der Position und der Wertpapierzusammensetzung von Redmile widerspiegelt (Stammaktien, Warrants, Vorzugsaktien, Optionen, RSUs).

Die 脛nderung k眉ndigt keine neuen K盲ufe oder Verk盲ufe an, sondern formalisert die h枚here Eigentumsgrenze, kl盲rt die Zusammensetzung des Nutznie脽eranteils und bekr盲ftigt die Sperrmechanismen, die darauf ausgelegt sind, das Eigentum auf 14,99 % der ausstehenden Stammaktien zu begrenzen.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2025

 

Commission File Number: 001-41169

 

 

Vertical Aerospace Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Unit 1 Camwal Court, Chapel Street

Bristol BS2 0UW

United Kingdom

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x        Form 40-F ¨

 

 

 

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On July 3, 2025, Vertical Aerospace Ltd. (“the Company”) issued a press release announcing the addition of certain individuals to its senior management team, a copy of which is furnished as 99.1 hereto.

 

 

 

 

INCORPORATION BY REFERENCE

 

Exhibit 99.1 (excluding the quotation from the Company’s Chief Executive Officer) is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-270756, File No. 333-284763 and File No. 333-287207) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Vertical Aerospace Ltd.
     
Date: July 3, 2025 By: /s/ Stuart Simpson
    Stuart Simpson
    Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

 

Exhibit
No.		   Description
     
99.1   Press release of Vertical Aerospace Ltd. dated July 3, 2025

 

 

Source:

FAQ

How many Fate Therapeutics (FATE) shares does Redmile now beneficially own?

The reporting group discloses 17,941,579 shares, or 14.9 % of outstanding common stock.

What change triggered this Schedule 13D/A amendment?

Redmile elected on 1 July 2025 to increase the warrant ownership blocker from 9.99 % to 14.99 %, enabling a larger reportable stake.

Will Fate Therapeutics receive cash from the warrant exercises?

Any remaining Pre-Funded Warrants carry a de-minimis $0.001 exercise price, so cash proceeds will be immaterial.

How much could Redmile鈥檚 position grow post-election?

The group can exercise or convert securities for up to 4.9 million additional shares while staying under the new 14.99 % threshold.

Does the filing suggest imminent share sales by Redmile?

No. The amendment focuses on ownership cap adjustments; it does not indicate sales intentions.

What is the impact on other shareholders?

Dilution risk rises modestly, and governance influence shifts toward a single large holder, but no change-of-control event is triggered.
Stock EVTL logo
Vertical Aerospace Ltd

NYSE:EVTL

EVTL Rankings

#4772 Ranked by Market Cap
N/A Ranked by Dividends

EVTL Latest News

Jul 3, 2025
Vertical Aerospace Expands Leadership Team With Key Executive Appointments
Jul 1, 2025
Vertical Aerospace Announces Date for AGM
Jun 12, 2025
Vertical and Bristow Partner to Deliver Full Service 'Ready-to-Fly' eVTOL Operations for VX4 Customers
Jun 3, 2025
Vertical Aerospace Appoints Former MI5 Director General Lord Andrew Parker to Board
May 27, 2025
Vertical Aerospace Makes Aviation History with Piloted eVTOL Flight in Open Airspace

EVTL Latest SEC Filings

Jul 1, 2025
[6-K] Vertical Aerospace Ltd. Current Report (Foreign Issuer)
Jun 26, 2025
[144] Vertical Aerospace Ltd. SEC Filing

EVTL Stock Data

524.54M
67.99M
19.65%
72.21%
0.66%
Aerospace & Defense
Industrials
United Kingdom
Bristol